Low- and Very Low-Dose Bevacizumab for Retinopathy of Prematurity: Reactivations, Additional Treatments, and 12-Month Outcomes

Sharon F Freedman,Amra Hercinovic,David K Wallace,Raymond T Kraker,Zhuokai Li,Amit R Bhatt,Charline S Boente,Eric R Crouch,G Baker Hubbard,David L Rogers,Deborah VanderVeen,Michael B Yang,Nathan L Cheung,Susan A Cotter,Jonathan M Holmes

Ophthalmology（2022）

引用 5|浏览13

暂无评分

摘要

Retinal structural outcomes were very good after low- and very low-dose IVB as initial treatment for type 1 ROP, although many eyes received additional treatment. The rate of reactivation of severe ROP was not associated with dose; however, a post hoc data-driven analysis suggested that reactivation was sooner with very low doses.

查看译文

关键词

Bevacizumab,Pediatric ophthalmology,Retinopathy of prematurity

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要